

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of **Icard-Liepkalns, et al.**

Serial No.: 09/595,947

Filed:

June 16, 2000

Title:

Polypeptides Of The "Basic Helix-Loop"

BHLH Family, Corresponding Nucleic

Acid Sequences

Examiner:

Not yet assigned

Art Unit:

1653

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

4-4-01

Delra Z

REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Attached is a copy of the official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that the "ATTY. Docket No." should read: "ST96042A" and, the "Applicants" should read: "Christine Icard-Liepkalns, Jacques Mallet, and Philippe Ravassard".

Applicants respectfully submit that the error is not due to any error by Applicants and thus no fee is required. However, if any fees are required, the Commissioner is hereby authorized to charge payment of said fees for this Request for Corrected Filing Receipt to Deposit Account 18-1982. An original and two duplicates of this sheet are enclosed.

Respectfully submitted,

Karen I. Krupen, Reg. #34,647

Attorney/Agent for Applicant

Customer No. 005487 Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-4658 Telefax (908) 231-2626 ST96042A US

5796042A



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/595,947	06/16/2000	1653	2142	5796042A	7	66	11

005487 AVENTIS PHARMACEUTICALS PRODUCTS INC ROUTE 202-206; MAIL STOP: EMC-G1 PO BOX 6800 BRIDGEWATER, NJ 08807



Date Mailed: 09/27/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) Christine Icard - Liepkalns, Jacques Mallet, Philippe Rava ssard.

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/331,356 07/12/1999 WHICH IS A 371 OF PCT/FR97/02368 12/19/1997

Foreign Applications

FRANCE FR96/15651 12/19/1996

If Required, Foreign Filing License Granted 09/26/2000

Title

Polypeptides of the "basic helix-loop-helix" BHLH family, corresponding nucleic acid sequences

Preliminary Class

514

Data entry by: ARMSTEAD, LORRAINE Team: OIPE Date: 09/27/2000

- 1 BANDA SULLA ANDRE NING ARINI BRITA BRITA







United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/595,947

06/16/2000

005487 AVENTIS PHARMACEUTICALS PRODUCTS INC ROUTE 202-206; MAIL STOP: EMC-G1 PO BOX 6800 BRIDGEWATER, NJ 08807

FORMALITIES LETTER

Date Mailed: 09/27/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

The balance due by applicant is \$ 130.

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Sérvice Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

09595947 04/10/2001 BHABTEW 0000006 181982 130.00 CH



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Icard-Liepkalns, et al.

Serial No.: 09/595,947

Filed:

June 16, 2000

Title:

Polypeptides Of The "Basic Helix-Loop"

BHLH Family, Corresponding Nucleic

Acid Sequences

Examiner:

Not yet assigned

Art Unit:

1653

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

4-4-01 Date of Deposit

Signature

<u>UNDER 37 C.F.R. 1.53(f)</u>

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING DATE GRANTED" which was mailed on September 27, 2000 and which indicated that the oath or declaration was missing, Applicants submit herewith the Declaration for the present application and a copy of Form PTO-1533.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

Respectfully submitted,

Karen I. Krupen, Reg. #34,64

Attorney/Agent for Applicant,

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626

Docket No. ST96042A